Pilot Study – Individualized Aromatherapy Applications in Patients with Gynecological Cancers: Experiences, Impact, and Context

Not Applicable

• Conditions: Individual therapy- and/or illness-related symptoms in post gynecological treatment; condition after gynecologic oncology cancer/ breast cancer; fostering general well-being.

• Registration Number: DRKS00024193
• Lead Sponsor: Charité - Universitätsmedizin Berlin, Klinik für Pädiatrie m. S. Onkologie/Hämatologie, AG Integrative Medizin in der pädiatrischen Onkologie

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-06-25
• Study Completion: 2021-10-30
• Results First Posted: 2022-12-23
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 18

Inclusion Criteria

Patient is undergoing follow-up care as a result of gynecological oncological disease/ breast cancer; at least 6 weeks have passed since the last intensive polychemotherapy; German language skills; written consent obtained for partici-pation and for the disclosure of pseudonymized data as part of the research documentation is available.

Exclusion Criteria

Allergies to the product or product-ingredients used; other existing diseases, skin changes, or health conditions that could interfere with treatment of participants according to the study protocol; participation in other studies that could interfere with study participation in the arth4WOMEN project.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
In the qualitative part of the study, the participants will be interviewed after the intervention with regard to their perceptions of and experiences with the intervention. The interviews will be semi-structured and include narrative and association-based components.

Secondary Outcome Measures

Name	Time	Method
Overview of participants’ personal illness- and/or treatment-related symptomatic burdens and the associated subjective stress level before and after the intervention. <br>Collection of data will take place as follows:<br>(1) At the beginning and end of the intervention:<br>MYMOP assessment of individual participant symptoms and general well-being <br>(2) During the intervention:<br>Collection of quantitative and qualitative data on products, used, time and mode of application by an applica-tion protocol (= documentation poster) completed by participants.<br>